USANA Health Sciences (NYSE:USNA) Trading 3.4% Higher - Time to Buy?

USANA Health Sciences, Inc. (NYSE:USNA - Get Free Report) traded up 3.4% during mid-day trading on Monday . The stock traded as high as $32.77 and last traded at $32.87. Approximately 32,805 shares were traded during trading, a decline of 75% from the average daily volume of 130,944 shares. The stock had previously closed at $31.78.

Analysts Set New Price Targets

A number of research analysts have recently commented on USNA shares. StockNews.com downgraded shares of USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research report on Friday, February 14th. Sidoti cut USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a report on Tuesday, February 18th. Finally, DA Davidson lowered their price target on USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating on the stock in a research report on Thursday.

USANA Health Sciences Price Performance

The stock has a market capitalization of $544.54 million, a P/E ratio of 10.10, a PEG ratio of 0.93 and a beta of 0.87. The stock's 50-day simple moving average is $33.62 and its 200 day simple moving average is $36.61.

USANA Health Sciences (NYSE:USNA - Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.15. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. The business had revenue of $213.61 million during the quarter, compared to analysts' expectations of $208.82 million. As a group, analysts expect that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current fiscal year.

Remove Ads

Institutional Trading of USANA Health Sciences

Hedge funds and other institutional investors have recently bought and sold shares of the business. Pzena Investment Management LLC raised its position in shares of USANA Health Sciences by 3.6% in the fourth quarter. Pzena Investment Management LLC now owns 1,087,076 shares of the company's stock valued at $39,015,000 after buying an additional 37,466 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of USANA Health Sciences by 7.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 773,228 shares of the company's stock valued at $27,751,000 after acquiring an additional 55,059 shares during the period. Pacer Advisors Inc. grew its holdings in shares of USANA Health Sciences by 8.8% during the 4th quarter. Pacer Advisors Inc. now owns 592,001 shares of the company's stock worth $21,247,000 after purchasing an additional 47,745 shares in the last quarter. State Street Corp raised its stake in USANA Health Sciences by 0.6% in the third quarter. State Street Corp now owns 435,164 shares of the company's stock valued at $16,501,000 after purchasing an additional 2,782 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in USANA Health Sciences by 1.6% during the fourth quarter. Geode Capital Management LLC now owns 301,949 shares of the company's stock worth $10,839,000 after purchasing an additional 4,829 shares during the period. Institutional investors and hedge funds own 54.25% of the company's stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.